You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
珍寶島(603567.SH):擬與恆諾康合作注射用HNC042的開發、生產和銷售工作
格隆匯 05-18 20:02

格隆匯5月18日丨珍寶島(603567.SH)公告,近日,公司與廣州市恆諾康醫藥科技有限公司(以下簡稱“恆諾康”或“乙方”)分別簽訂了《技術轉讓及新藥研發合同》和《技術轉讓及新藥研發合同之補充協議》,擬合作共同開展注射用HNC042的開發、生產和銷售工作。

我國目前抗流感病毒治療已上市的藥物有神經氨酸酶抑制劑、血凝素抑制劑和M2離子通道阻滯劑三種,HNC042用於預防和治療流感,尤其是需要住院接受靜脈注射治療的流感重症患者,屬於神經氨酸酶抑制劑類抗流感病毒藥物,對野生型及耐藥突變型(H274Y)的神經氨酸酶都表現出很高的抑制活性。注射用HNC042項目已在美國完成I期臨牀試驗,結果顯示安全性及耐受性較好,PK呈線性,支持開展Ⅱ期臨牀試驗。2018年10月已獲得國內臨牀批件,即將啟動國內臨牀試驗。注射用HNC042項目的同類產品主要為帕拉米韋氯化鈉注射液,該產品目前已在美國、日本和中國等國家上市,國外生產公司為美國BioCrystPharmaceuticals公司;國內生產公司為湖南南新制藥股份有限公司,帕拉米韋氯化鈉注射液為該公司獨家品種,於2013年上市,近幾年市場規模增長速度較大。

該合同的履行是公司推動“引進合作與自主研發並行”模式邁出的堅實一步,標誌着公司在化學創新藥領域登上一個新的台階。注射用HNC042品種和相關權益的引入有利於升級公司抗病毒藥物產品管線,形成化學創新藥研發品種梯隊,提高公司創新藥的研發實力,增強公司在創新藥領域的競爭力,提升公司未來整體盈利能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account